All In Biotech

Drug Trial Radar · NCT06297941

Study of REM-422 in Patients With AML or Higher Risk MDS

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Apr 26, 2024

Primary completion

Jul 31, 2027

Study completion Mar 30, 2028

Sponsor

Lead sponsor
Remix TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

Conditions

  • Myelodysplastic Syndromes
  • Higher Risk Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Refractory

Interventions

  • REM-422Drug

    REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor REM-422 will be administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: 24 months
  2. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)Time frame: Assessed at the end of Cycle 1 (each cycle is 28 days) for each participant for approximately 24 months

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Bordeaux

    Bordeaux, France · Recruiting

  • AP-HP - Hôpital Saint-Louis

    Paris, France · Recruiting

  • IUCT-Oncopole

    Toulouse, France · Recruiting

  • Institut de Cancerologie Gustave-Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.